Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?

被引：3

作者：

Chen, Hsin-Hua ^{[1
,2
,3
,4
,5
,6
,7
]}

Chen, Der-Yuan ^{[1
,2
,3
,7
,8
,9
]}

Chen, Yi-Ming ^{[1
,2
,3
]}

Tang, Chao-Hsiun ^{[10
]}

机构：

[1] Taichung Vet Gen Hosp, Dept Med Res, 1650 Taiwan Blvd Sect 4, Taichung 40705, Taiwan

[2] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan

[3] Taichung Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, Taichung, Taiwan

[4] Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan

[5] Natl Yang Ming Univ, Community Med Res Ctr, Taipei 112, Taiwan

[6] Natl Yang Ming Univ, Inst Hosp & Hlth Care Adm, Taipei 112, Taiwan

[7] Chung Shan Med Univ, Sch Med, Taichung, Taiwan

[8] Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan

[9] Taichung Vet Gen Hosp, Dept Med Educ, Taichung, Taiwan

[10] Taipei Med Univ, Sch Hlth Care Adm, Taipei, Taiwan

来源：

PATIENT PREFERENCE AND ADHERENCE | 2016年 / 10卷

关键词：

adalimumab; etanercept; methotrexate; rheumatoid arthritis; treatment discontinuation; TUMOR-NECROSIS-FACTOR; ANTI-TNF THERAPY; MONOCLONAL-ANTIBODY; TREATMENT FAILURE; BRITISH SOCIETY; TUBERCULOSIS; COMBINATION; CRITERIA; IMMUNOGENICITY; ASSOCIATION;

D O I：

10.2147/PPA.S94396

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: To compare drug discontinuation risk between adalimumab (ADA) and etanercept (ETN) treatment among anti-tumor necrosis factor (anti-TNF)-naive rheumatoid arthritis (RA) patients, in particular the influence of concomitant dose of methotrexate (MTX). Methods: This retrospective nationwide population-based cohort study identified 4,592 anti-TNF-naive RA patients in whom ETN (n=2,609) or ADA (n=1,983) was initiated using National Health Insurance claims data. After adjustment for prior medication, concomitant medication, and baseline demographic data, the relative risk of drug discontinuation in ADA users compared with ETN users was quantified by calculating adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) using Cox proportional hazard regression analyses, stratified by the follow-up time (<= 1 year, >1 year) and/or concomitant MTX dose (<= 10 mg/wk, >10 mg/wk). Results: ADA users had a higher risk of drug discontinuation compared with ETN users during the first year of follow-up (aHR, 1.13; 95% CI, 1.01-1.27), but not during all treatment periods (aHR, 1.06; 95% CI, 0.98-1.16) or after 1 year (aHR, 0.99; 95% CI, 0.87-1.13). However, ADA users had a significantly higher risk of drug discontinuation compared with ETN users among patients on concomitant MTX > 10 mg/wk during all treatment periods (aHR, 1.27; 95% CI, 1.10-1.47), during the first year of follow-up (aHR, 1.48; 95% CI, 1.22-1.78), or after 1 year (aHR, 1.42; 95% CI, 1.06-1.90), but not among patients on concomitant MTX 0-10 mg/wk. Conclusion: This population-based cohort study demonstrated a modification effect of concomitant MTX dose on the relative risk of anti-TNF discontinuation for ADA compared with ETN among anti-TNF-naive RA patients. However, the lack of exact cause of anti-TNF discontinuation limited causal inference of such a concomitant MTX dose-related modification effect.

引用

页码：123 / 134

页数：12

共 36 条

[1] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].